{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:48:11Z","timestamp":1788482891183,"version":"build-2803163510"},"reference-count":53,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:p>\n                    Dry eye disease (DED) is a multifactorial disorder characterized by disruption of tear film homeostasis, resulting in ocular surface inflammation and damage. Although several Food and Drug Administration-approved topical treatments are available, direct comparisons of their efficacy and safety are complicated by variability in study designs and corneal staining grading scales. This review systematically evaluates and compares the efficacy and safety of topical therapies approved in the United States, focusing on anti-inflammatory and semi-fluorinated alkane (SFA)-based therapies. A systematic literature review identified 12 randomized controlled trials involving a total of 6,984 patients with varying severity of DED eligible for inclusion, with 8 providing data suitable for quantitative meta-analysis and 5 for exploratory regression analysis. Meta-analysis indicated that cyclosporine 0.1%\/SFA showed the most significant early improvement (within \u22644 weeks) in total corneal fluorescein staining, outperforming other treatments. Exploratory regression analysis further supported these findings, demonstrating that cyclosporine 0.1%\/SFA had the fastest and most consistent reduction in corneal staining, with the steepest improvement slope and strong predictability (\n                    <jats:italic toggle=\"yes\">R<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    = 0.871). Safety analyses highlighted improved local tolerability for SFA-based therapies compared with traditional anti-inflammatory treatments, notably lower instillation site discomfort for both cyclosporine 0.1%\/SFA (2.5%\u20139.9%) and perfluorohexyloctane (\u22641%) vs. other cyclosporine formulations. SFA-based therapies, especially cyclosporine 0.1%\/SFA, demostrated robust efficacy in improving signs of DED with superior tolerability profiles compared to traditional anti-inflammatory treatments. These findings support the role in effectively managing ocular surface inflammation and optimizing treatment strategies in DED.\n                  <\/jats:p>","DOI":"10.1089\/jop.2024.0192","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T11:34:37Z","timestamp":1745840077000},"page":"293-304","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":7,"title":["Comparative Efficacy of Current Topical Treatments for Dry Eye Disease: A Review of Pivotal Clinical Trials Evaluating Corneal Staining Outcomes"],"prefix":"10.1177","volume":"41","author":[{"given":"Ahmad","family":"Fahmy","sequence":"first","affiliation":[{"name":"Minnesota Eye Consultants, Minnetonka, Minnesota, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masih","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Pflugfelder","sequence":"additional","affiliation":[{"name":"Cullen Eye Institute, Baylor College of Medicine, Houston, Texas, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3764-5377","authenticated-orcid":false,"given":"Anara","family":"Serikbaeva","sequence":"additional","affiliation":[{"name":"Harrow Inc, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Wei","family":"Tsao","sequence":"additional","affiliation":[{"name":"Harrow Inc, Nashville, Tennessee, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"e_1_3_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.003"},{"key":"e_1_3_6_3_2","unstructured":"USA General Population. 2018. Cross-Sectional Study and Census.gov Population Clock. Available from: https:\/\/www.census.gov\/popclock\/ [Last accessed May18 2023]."},{"key":"e_1_3_6_4_2","doi-asserted-by":"publisher","DOI":"10.4103\/sjopt.sjopt_190_21"},{"key":"e_1_3_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2015-308237"},{"key":"e_1_3_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2019.03.023"},{"key":"e_1_3_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2017.05.011"},{"key":"e_1_3_6_8_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2022.05.20"},{"issue":"2","key":"e_1_3_6_9_2","first-page":"240","article-title":"Dry eye: An inflammatory ocular disease","volume":"9","author":"Hessen M","year":"2014","unstructured":"Hessen M, , Karamursel Akpek E. Dry eye: An inflammatory ocular disease. Journal of Ophthalmic & Vision Research [Internet], 2014; 9(2):240. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4181208\/","journal-title":"Journal of Ophthalmic & Vision Research [Internet]"},{"key":"e_1_3_6_10_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.815075"},{"key":"e_1_3_6_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S89700"},{"key":"e_1_3_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2018.06.026"},{"key":"e_1_3_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2015.01.016"},{"key":"e_1_3_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.08.024"},{"issue":"4","key":"e_1_3_6_15_2","first-page":"221","article-title":"Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes","volume":"21","author":"Lemp A","year":"1995","unstructured":"Lemp A. Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes. Eye & Contact Lens, 1995; 21(4):221\u2013232.","journal-title":"Eye & Contact Lens"},{"key":"e_1_3_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2019.01.004"},{"key":"e_1_3_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICL.0000000000000636"},{"key":"e_1_3_6_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S175065"},{"key":"e_1_3_6_19_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S392315"},{"key":"e_1_3_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.03.050"},{"key":"e_1_3_6_21_2","unstructured":"Restasis (cyclosporine ophthalmic emulsion) [product monogram]. Irvine CA: Allergan 2017. Available from: https:\/\/www.abbvie.ca\/content\/dam\/abbvie-dotcom\/ca\/en\/documents\/products\/RESTASIS_PM_EN.pdf"},{"key":"e_1_3_6_22_2","unstructured":"U.S. Food and Drug Administration. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-023_Restasis.cfm [Last accessed: December11 2018]."},{"key":"e_1_3_6_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(99)00176-1"},{"key":"e_1_3_6_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000002633"},{"key":"e_1_3_6_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.0709"},{"key":"e_1_3_6_26_2","first-page":"10","article-title":"Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE","volume":"13","author":"Wirta DL","year":"2022","unstructured":"Wirta DL, , Galor A, , Aune CA, et al. Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE. Cornea, 2022; 13:10\u201397.","journal-title":"Cornea"},{"key":"e_1_3_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.01.024"},{"key":"e_1_3_6_28_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.0101"},{"key":"e_1_3_6_29_2","unstructured":"Xiidra (lifitegrast) [package insert]. Lexington MA: Shire US Inc 2016. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/208073s000lbl.pdf"},{"key":"e_1_3_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2016.01.001"},{"key":"e_1_3_6_31_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2016.0105"},{"key":"e_1_3_6_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/2515841419870366"},{"key":"e_1_3_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.09.015"},{"key":"e_1_3_6_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.08.001"},{"key":"e_1_3_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.09.025"},{"key":"e_1_3_6_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2021.3943"},{"key":"e_1_3_6_37_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672118791936"},{"key":"e_1_3_6_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000000803"},{"key":"e_1_3_6_39_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.709712"},{"key":"e_1_3_6_40_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1006444615412"},{"key":"e_1_3_6_41_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210001000301"},{"key":"e_1_3_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtos.2019.02.010"},{"key":"e_1_3_6_43_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041211"},{"key":"e_1_3_6_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2022.12.021"},{"key":"e_1_3_6_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2023.03.008"},{"key":"e_1_3_6_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICO.0000000000003418"},{"key":"e_1_3_6_47_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2023.0270"},{"key":"e_1_3_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2023.100704"},{"key":"e_1_3_6_49_2","volume-title":"Elements of numerical mathematical economics with Excel: static and dynamic optimization","author":"Romeo G","year":"2020","unstructured":"Romeo G. Elements of numerical mathematical economics with Excel: static and dynamic optimization. London: Academic Press, an imprint of Elsevier; 2020."},{"key":"e_1_3_6_50_2","doi-asserted-by":"publisher","DOI":"10.1302\/2046-3758.49.2000571"},{"key":"e_1_3_6_51_2","unstructured":"Johnston J. Effect of OTX-101 0.09% on corneal staining and SANDE scores in patients with dry eye disease uncontrolled on cyclosporine ophthalmic emulsion 0.05%. Abstract presented at American Academy of Optometry 2023; October 12 2023; New Orleans LA."},{"key":"e_1_3_6_52_2","unstructured":"Karpecki P Barghout V Schenkel B et al. A retrospective analysis of real-world treatment patterns in patients with dry eye disease receiving CEQUA Restasis\u00ae or Xiidra\u00ae. Poster presented at AMCP Nexus; October 11\u201314 2022; National Harbor MD."},{"key":"e_1_3_6_53_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S233194"},{"key":"e_1_3_6_54_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S226168"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2024.0192","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0192","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2024.0192","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:46:58Z","timestamp":1777646818000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2024.0192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,1]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8,1]]}},"alternative-id":["10.1089\/jop.2024.0192"],"URL":"https:\/\/doi.org\/10.1089\/jop.2024.0192","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,1]]}}}